StemRIM Inc. ( (JP:4599) ) just unveiled an announcement.
StemRIM Inc. announced the interim analysis results of its global Phase 2b clinical trial for Redasemtide, a treatment for acute ischemic stroke, conducted in collaboration with Shionogi & Co., Ltd. The trial, which spans 18 countries, aims to evaluate Redasemtide’s efficacy in patients not eligible for endovascular recanalization therapy. The interim analysis recommended continuing the trial for the 1.5 mg/kg dose group while discontinuing the 0.75 mg/kg group, aligning with initial expectations and potentially reducing the required number of subjects. This development is significant for the clinical advancement of Redasemtide, although it currently has no impact on StemRIM’s financial results for the fiscal year ending July 31, 2025.
More about StemRIM Inc.
StemRIM Inc. is a biotech venture originating from Osaka University, focused on developing ‘Regeneration-Inducing Medicine’ which aims to achieve regenerative therapy effects through drug administration without using living cells or tissues. The company is advancing its regenerative medicine products to mobilize mesenchymal stem cells for tissue repair and regeneration, targeting various diseases including acute ischemic stroke, cardiomyopathy, and osteoarthritis.
YTD Price Performance: 0.96%
Average Trading Volume: 114,538
Technical Sentiment Signal: Buy
Current Market Cap: Yen19.73B
Find detailed analytics on 4599 stock on TipRanks’ Stock Analysis page.